CorMedix Inc. (CRMD) is the 202nd largest of 300 Pharmaceuticals companies by market capitalisation, at 654.73 Mn, behind Aquestive Therapeutics, Inc. at 670.23 Mn. It trades on a P/E of 5.25, 73% below the peer median of 19.66. The table below compares all 300 on 8 financial metrics.
| # | Ticker | Company | match | industry_code | industry_group | industry_group_code | Market Capitalization | P/E | P/S | Enterprise Value |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JNJ | Johnson & Johnson | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 663.08 Bn | 31.49 | 6.77 | 642.33 Bn |
| 2 | ABBV | AbbVie Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 453.04 Bn | 71.80 | 7.04 | 446.51 Bn |
| 3 | MRK | Merck & Co., Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 370.87 Bn | 117.16 | 5.57 | 363.78 Bn |
| 4 | NVS | Novartis Ag | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 305.29 Bn | 10.77 | 4.44 | 298.00 Bn |
| 5 | PFE | Pfizer Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 162.10 Bn | 37.11 | 2.54 | 150.70 Bn |
| 6 | SNY | Sanofi | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 53.95 Bn | 11.58 | 1.01 | 46.98 Bn |
| 7 | RVMD | Revolution Medicines, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 45.00 Bn | -25.05 | — | 45.00 Bn |
| 8 | INCY | Incyte Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 25.47 Bn | 15.75 | 4.38 | 20.94 Bn |
| 9 | UTHR | UNITED THERAPEUTICS Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 20.81 Bn | 15.85 | 6.60 | 18.15 Bn |
| 10 | JAZZ | Jazz Pharmaceuticals plc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 16.02 Bn | 16.58 | 3.48 | 14.40 Bn |
| 11 | NBIX | Neurocrine Biosciences Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 15.81 Bn | 22.28 | 4.69 | 15.42 Bn |
| 12 | EXEL | Exelixis, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 14.69 Bn | 17.20 | 6.03 | 13.85 Bn |
| 13 | CORT | Corcept Therapeutics Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 12.07 Bn | 217.01 | 14.52 | 11.76 Bn |
| 14 | AXSM | Axsome Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 10.81 Bn | -69.64 | 13.92 | 10.49 Bn |
| 15 | GPCR | Structure Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 10.11 Bn | -54.84 | — | 10.11 Bn |
| 16 | CYTK | Cytokinetics Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 10.11 Bn | -13.09 | 149.40 | 8.94 Bn |
| 17 | NUVL | Nuvalent, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 9.75 Bn | -27.07 | — | 9.75 Bn |
| 18 | KYMR | Kymera Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 9.72 Bn | -38.47 | 92.56 | 9.03 Bn |
| 19 | CRNX | Crinetics Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 8.99 Bn | -17.90 | 213.22 | 8.99 Bn |
| 20 | ALKS | Alkermes plc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 7.72 Bn | 116.43 | 4.63 | 7.07 Bn |
| 21 | BLTE | Belite Bio, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 7.62 Bn | 0.09 | — | 7.62 Bn |
| 22 | TVTX | Travere Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 6.15 Bn | -140.40 | 10.40 | 6.03 Bn |
| 23 | LQDA | Liquidia Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 6.12 Bn | 44.04 | 13.57 | 5.83 Bn |
| 24 | AMRN | Amarin Corp Plc\Uk | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 5.73 Bn | -209.27 | 30.74 | 5.41 Bn |
| 25 | ACAD | Acadia Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.82 Bn | 12.64 | 4.24 | 3.87 Bn |
| 26 | EWTX | Edgewise Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.64 Bn | -23.51 | — | 4.64 Bn |
| 27 | ELVN | Enliven Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.35 Bn | -46.65 | — | 4.35 Bn |
| 28 | DFTX | Definium Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.22 Bn | -11.92 | — | 4.22 Bn |
| 29 | INDV | Indivior Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.12 Bn | 11.71 | 3.10 | 3.90 Bn |
| 30 | MANE | Veradermics, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.11 Bn | -46.17 | — | 4.11 Bn |
| 31 | TARS | Tarsus Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 3.93 Bn | -83.93 | 6.48 | 3.48 Bn |
| 32 | CPRX | CATALYST PHARMACEUTICALS, INC. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 3.85 Bn | 17.94 | 6.45 | 3.09 Bn |
| 33 | OGN | Organon & Co. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 3.62 Bn | 17.31 | 0.59 | 2.49 Bn |
| 34 | NAMS | NewAmsterdam Pharma Co N.V. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.99 Bn | -12.08 | 419.65 | 2.99 Bn |
| 35 | TAK | Takeda Pharmaceutical Co Ltd | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.67 Bn | 4.61 | 0.06 | -3.12 Bn |
| 36 | SUPN | Supernus Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.53 Bn | -29.70 | 3.21 | 2.16 Bn |
| 37 | MLYS | Mineralys Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.49 Bn | -6.84 | — | 2.49 Bn |
| 38 | BEIGF | BeOne Medicines Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.48 Bn | 3.74 | 0.40 | -2.62 Bn |
| 39 | TRVI | Trevi Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.46 Bn | -64.08 | — | 2.46 Bn |
| 40 | HRMY | Harmony Biosciences Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.46 Bn | 13.72 | 2.56 | 1.65 Bn |
| 41 | NUVB | Nuvation Bio Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.36 Bn | -21.96 | 13.89 | 2.36 Bn |
| 42 | PVLA | Palvella Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.26 Bn | -42.59 | — | 1.95 Bn |
| 43 | AUPH | Aurinia Pharmaceuticals Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.14 Bn | 6.66 | 6.86 | 1.69 Bn |
| 44 | ETON | Eton Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.65 Bn | 169.20 | 16.49 | 1.63 Bn |
| 45 | INVA | Innoviva, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.55 Bn | 7.98 | 3.01 | 0.97 Bn |
| 46 | XERS | Xeris Biopharma Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.48 Bn | -85.88 | 4.41 | 1.36 Bn |
| 47 | HROW | Harrow, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.44 Bn | -43.03 | 5.24 | 1.36 Bn |
| 48 | LBRX | Lb Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.42 Bn | -24.58 | — | 1.42 Bn |
| 49 | OPK | Opko Health, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.22 Bn | -32.69 | 2.08 | 0.92 Bn |
| 50 | KURA | Kura Oncology, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.18 Bn | -4.95 | 15.26 | 1.18 Bn |
| 51 | PCRX | Pacira BioSciences, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.05 Bn | 71.04 | 1.41 | 0.80 Bn |
| 52 | LXRX | Lexicon Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.00 Bn | -15.59 | 24.14 | 0.81 Bn |
| 53 | SGP | SpyGlass Pharma, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.97 Bn | -48.72 | — | 0.97 Bn |
| 54 | DSGN | Design Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.95 Bn | -11.70 | — | 0.74 Bn |
| 55 | OLMA | Olema Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.94 Bn | -5.50 | — | 0.94 Bn |
| 56 | COLL | Collegium Pharmaceutical, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.76 Bn | 15.94 | 0.95 | 0.62 Bn |
| 57 | PHAT | Phathom Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.76 Bn | -8.10 | 3.17 | 0.58 Bn |
| 58 | VSTM | Verastem, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.74 Bn | -7.12 | 8.48 | 0.61 Bn |
| 59 | ZVRA | Zevra Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.74 Bn | 12.59 | 5.40 | 0.51 Bn |
| 60 | GYRE | Gyre Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.73 Bn | -37.38 | 6.09 | 0.70 Bn |
| 61 | IVEVF | Inventiva S.A. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.69 Bn | 7.19 | 132.94 | 0.69 Bn |
| 62 | AQST | Aquestive Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.67 Bn | -8.53 | 12.39 | 0.57 Bn |
| 63 | CRMD | CorMedix Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.65 Bn | 5.25 | 1.75 | 0.40 Bn |
| 64 | NVCT | Nuvectis Pharma, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.65 Bn | -18.99 | — | 0.65 Bn |
| 65 | MPLT | MapLight Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.63 Bn | -3.10 | — | 0.63 Bn |
| 66 | EOLS | Evolus, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.61 Bn | -17.86 | 1.94 | 0.57 Bn |
| 67 | SPRY | ARS Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.56 Bn | -2.52 | 4.78 | 0.41 Bn |
| 68 | OVID | Ovid Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.52 Bn | -16.03 | 326.79 | 0.40 Bn |
| 69 | XFOR | X4 Pharmaceuticals, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.51 Bn | -5.66 | 32.21 | 0.32 Bn |
| 70 | IKT | Inhibikase Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.44 Bn | -6.67 | — | 0.38 Bn |
| 71 | VTVT | vTv Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.41 Bn | -87.02 | 11.23 | 0.41 Bn |
| 72 | ACHV | Achieve Life Sciences, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.37 Bn | — | — | 0.37 Bn |
| 73 | PALI | Palisade Bio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.36 Bn | -12.52 | 725.63 | 0.24 Bn |
| 74 | VNDA | Vanda Pharmaceuticals Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.33 Bn | -1.19 | 1.52 | 0.16 Bn |
| 75 | SION | Sionna Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.32 Bn | -3.33 | — | 0.32 Bn |
| 76 | EBS | Emergent BioSolutions Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.32 Bn | -1.81 | 0.41 | 0.18 Bn |
| 77 | IMRX | Immuneering Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.31 Bn | -5.31 | — | 0.31 Bn |
| 78 | FULC | Fulcrum Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.29 Bn | -3.30 | — | 0.29 Bn |
| 79 | TTRX | Turn Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.29 Bn | -37.91 | — | 0.29 Bn |
| 80 | CELG-RI | Bristol Myers Squibb Co | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.29 Bn | 0.03 | 0.01 | -10.78 Bn |
| 81 | ZNTL | Zentalis Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.29 Bn | -2.04 | — | 0.29 Bn |
| 82 | AKBA | Akebia Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | -8.82 | 1.20 | 0.11 Bn |
| 83 | SIGA | Siga Technologies Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.24 Bn | — | — | 0.08 Bn |
| 84 | TNXP | Tonix Pharmaceuticals Holding Corp. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -1.37 | 7.58 | 0.22 Bn |
| 85 | CRDL | Cardiol Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -7.36 | — | 0.22 Bn |
| 86 | DERM | Journey Medical Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -59.11 | 3.17 | 0.19 Bn |
| 87 | NERV | Minerva Neurosciences, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | -31.43 | — | 0.21 Bn |
| 88 | ACOG | Alpha Cognition Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | -7.55 | 15.49 | 0.17 Bn |
| 89 | SLGL | Sol-Gel Technologies Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | -18.47 | 107.91 | 0.15 Bn |
| 90 | MCUJF | Medicure Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | -37.45 | 8.18 | 0.19 Bn |
| 91 | LENZ | LENZ Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | -1.45 | 8.72 | 0.19 Bn |
| 92 | MENS | Jyong Biotech Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | -46.69 | — | 0.18 Bn |
| 93 | LONA | LeonaBio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | -1.47 | — | 0.13 Bn |
| 94 | BMEA | Biomea Fusion, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | -2.60 | — | 0.15 Bn |
| 95 | VANI | Vivani Medical, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -4.77 | — | 0.11 Bn |
| 96 | NTHI | Neonc Technologies Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -2.79 | — | 0.13 Bn |
| 97 | AARD | Aardvark Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | -1.68 | — | 0.04 Bn |
| 98 | CPIX | Cumberland Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -9.44 | 3.25 | 0.10 Bn |
| 99 | CGTX | Cognition Therapeutics Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -2.55 | — | 0.10 Bn |
| 100 | VRCA | Verrica Pharmaceuticals Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -3.59 | 3.00 | 0.08 Bn |
| 101 | RGC | Regencell Bioscience Holdings Ltd | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | — | — | 0.09 Bn |
| 102 | PTHS | Pelthos Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -0.76 | 1.66 | 0.06 Bn |
| 103 | TENX | Tenax Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -1.35 | — | 0.09 Bn |
| 104 | MNOV | Medicinova Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -6.98 | 91.85 | 0.08 Bn |
| 105 | PLRX | Pliant Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -0.78 | — | 0.07 Bn |
| 106 | PMVP | PMV Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -1.14 | — | -0.01 Bn |
| 107 | BOLD | Boundless Bio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -1.01 | — | 0.06 Bn |
| 108 | VERU | Veru Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | 121.51 | — | 0.04 Bn |
| 109 | ANVS | Annovis Bio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -1.06 | — | 0.06 Bn |
| 110 | GOSS | Gossamer Bio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -0.34 | 1.08 | 0.00 Bn |
| 111 | KPTI | Karyopharm Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.26 | 0.35 | -0.01 Bn |
| 112 | CLNN | Clene Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -1.43 | 235.39 | 0.05 Bn |
| 113 | IXHL | Incannex Healthcare Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.83 | — | 0.04 Bn |
| 114 | APRE | Aprea Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -3.39 | — | 0.04 Bn |
| 115 | SCLX | Scilex Holding Co | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.08 | 1.20 | -0.08 Bn |
| 116 | ACTU | Actuate Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.70 | — | 0.04 Bn |
| 117 | GRCE | Grace Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -1.82 | — | 0.03 Bn |
| 118 | NSRX | Nasus Pharma Ltd | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -5.64 | — | 0.03 Bn |
| 119 | CPHI | China Pharma Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -7.43 | 8.49 | 0.03 Bn |
| 120 | UG | United Guardian Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 14.50 | 2.93 | 0.02 Bn |
| 121 | CRVO | CervoMed Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -0.86 | 79.16 | 0.03 Bn |
| 122 | YARW | Yarrow Bioscience, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -1.24 | 51.63 | 0.00 Bn |
| 123 | TXMD | TherapeuticsMD, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -138.26 | 7.82 | 0.02 Bn |
| 124 | BYSI | BeyondSpring Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -3.02 | — | 0.03 Bn |
| 125 | ATOS | Atossa Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -0.74 | — | 0.03 Bn |
| 126 | AYTU | Aytu Biopharma, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.76 | 0.42 | 0.00 Bn |
| 127 | BFRI | Biofrontera Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -4.42 | 0.51 | 0.02 Bn |
| 128 | ALLR | Allarity Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -1.87 | 903.73 | 0.02 Bn |
| 129 | MIRA | Mira Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.54 | — | 0.01 Bn |
| 130 | TVRD | Tvardi Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.68 | — | 0.02 Bn |
| 131 | CTXR | Citius Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.33 | 2.28 | 0.03 Bn |
| 132 | KPRX | Kiora Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -1.43 | — | 0.02 Bn |
| 133 | ANEB | Anebulo Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -1.64 | — | 0.01 Bn |
| 134 | INTI | Inhibitor Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -3.67 | — | 0.01 Bn |
| 135 | CALC | CalciMedica, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.35 | -8.79 | -0.01 Bn |
| 136 | CURX | Curanex Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.97 | — | 0.00 Bn |
| 137 | RVPH | Reviva Pharmaceuticals Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.78 | — | 0.01 Bn |
| 138 | ACXP | Acurx Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.81 | — | 0.01 Bn |
| 139 | PCSA | Processa Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.42 | — | 0.01 Bn |
| 140 | TRAW | Traws Pharma, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.35 | — | 0.00 Bn |
| 141 | PULM | Pulmatrix, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -1.25 | — | 0.01 Bn |
| 142 | TCRT | Alaunos Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.98 | 1,350.80 | 0.00 Bn |
| 143 | CVKD | Cadrenal Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.30 | — | 0.00 Bn |
| 144 | BICX | BioCorRx Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -1.64 | 6.70 | 0.00 Bn |
| 145 | ADXN | Addex Therapeutics Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.05 | — | 0.00 Bn |
| 146 | CASIF | CASI Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.02 | 0.12 | 0.00 Bn |
| 147 | OGEN | Oragenics Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.23 | — | 0.00 Bn |
| 148 | CANF | Can-Fite BioPharma Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.24 | 5.93 | 0.00 Bn |
| 149 | UPC | Universe Pharmaceuticals INC | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | — | — | -1,490.23 Bn |
| 150 | JAGX | Jaguar Health, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.01 | 0.05 | -0.01 Bn |
| 151 | ENSC | Ensysce Biosciences, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | — | — | 0.00 Bn |
| 152 | MTNB | Matinas BioPharma Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.16 | — | 0.00 Bn |
| 153 | SKVI | Skinvisible, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -1.05 | 54.04 | 0.00 Bn |
| 154 | SPRC | SciSparc Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.05 | 0.76 | 0.00 Bn |
| 155 | NCEL | NewcelX Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.06 | — | 0.00 Bn |
| 156 | GLMD | Galmed Pharmaceuticals Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | — | — | 0.00 Bn |
| 157 | CDT | CDT Equity Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.01 | — | 0.00 Bn |
| 158 | GCAN | Trafalgar International, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -1.77 | — | 0.00 Bn |
| 159 | CINGW | Cingulate Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 | — | 0.00 Bn |
| 160 | SXTC | China SXT Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 | 0.03 | -0.03 Bn |
| 161 | CMND | Clearmind Medicine Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 | — | -0.01 Bn |
| 162 | AMGN | Amgen Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 236.37 Bn | 27.00 | 6.20 | 222.38 Bn |
| 163 | GILD | Gilead Sciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 187.38 Bn | -64.83 | 6.15 | 184.12 Bn |
| 164 | VRTX | Vertex Pharmaceuticals Inc / Ma | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 138.36 Bn | 31.45 | 10.99 | 130.51 Bn |
| 165 | REGN | Regeneron Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 85.09 Bn | 19.66 | 5.48 | 77.10 Bn |
| 166 | ARGX | Argenx Se | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 63.93 Bn | 36.92 | 12.23 | 58.75 Bn |
| 167 | MRNA | Moderna, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 58.07 Bn | -18.38 | 26.07 | 52.94 Bn |
| 168 | TEVA | Teva Pharmaceutical Industries Ltd | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 42.34 Bn | 60.81 | 2.45 | 38.68 Bn |
| 169 | ALNY | Alnylam Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 35.59 Bn | 45.89 | 7.41 | 32.28 Bn |
| 170 | ALC | Alcon Inc | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 34.36 Bn | 54.08 | 3.19 | 32.91 Bn |
| 171 | BIIB | Biogen Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 32.63 Bn | 39.08 | 3.25 | 31.34 Bn |
| 172 | GEHC | GE HealthCare Technologies Inc. | secondary | H-08 | Medical Devices and Diagnostics | HG-02 | 31.10 Bn | 15.21 | 1.46 | 29.22 Bn |
| 173 | INSM | INSMED Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 27.57 Bn | -31.36 | 24.23 | 26.41 Bn |
| 174 | BNTX | BioNTech SE | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 26.24 Bn | -14.72 | 8.48 | 12.58 Bn |
| 175 | ROIV | Roivant Sciences Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 25.24 Bn | -16.96 | 2,310.98 | 25.93 Bn |
| 176 | VTRS | Viatris Inc | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 19.39 Bn | -47.81 | 1.32 | 18.50 Bn |
| 177 | ZBH | Zimmer Biomet Holdings, Inc. | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 18.70 Bn | 22.24 | 2.20 | 18.30 Bn |
| 178 | ASND | Ascendis Pharma A/S | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 16.77 Bn | 18.91 | 11.83 | 15.82 Bn |
| 179 | MDGL | Madrigal Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 15.77 Bn | -49.43 | 12.28 | 14.93 Bn |
| 180 | BBIO | BridgeBio Pharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 14.62 Bn | -21.18 | 20.50 | 13.91 Bn |
| 181 | BWXT | BWX Technologies, Inc. | secondary | I-39 | Clean Energy Equipment | IG-10 | 14.44 Bn | 40.58 | 4.11 | 13.83 Bn |
| 182 | SMMT | Summit Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 13.96 Bn | — | — | 13.27 Bn |
| 183 | BMRN | Biomarin Pharmaceutical Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.88 Bn | 176.35 | 3.78 | 12.00 Bn |
| 184 | HALO | Halozyme Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.57 Bn | 31.25 | 7.55 | 12.34 Bn |
| 185 | ARWR | Arrowhead Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.19 Bn | -45.49 | 18.20 | 10.58 Bn |
| 186 | KNSA | Kiniksa Pharmaceuticals International, plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.15 Bn | 74.93 | 14.45 | 11.63 Bn |
| 187 | AAVXF | Abivax S.A. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.92 Bn | -25.97 | — | 10.92 Bn |
| 188 | GMED | Globus Medical Inc | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 10.51 Bn | 19.74 | 3.34 | 9.91 Bn |
| 189 | GKOS | GLAUKOS Corp | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 10.46 Bn | -66.34 | 17.06 | 10.34 Bn |
| 190 | APGE | Apogee Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.18 Bn | -34.62 | — | 9.20 Bn |
| 191 | RDY | Dr Reddys Laboratories Ltd | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 9.99 Bn | 789.75 | 2.73 | 9.85 Bn |
| 192 | PRAX | Praxis Precision Medicines, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.82 Bn | -26.87 | — | 9.06 Bn |
| 193 | IONS | Ionis Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.62 Bn | -45.28 | 11.01 | 7.57 Bn |
| 194 | PTGX | Protagonist Therapeutics, Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.42 Bn | 87.02 | 33.42 | 9.42 Bn |
| 195 | PCVX | Vaxcyte, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.86 Bn | -8.36 | — | 8.86 Bn |
| 196 | TGTX | Tg Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.57 Bn | 17.97 | 10.72 | 7.89 Bn |
| 197 | IBRX | ImmunityBio, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.51 Bn | -8.55 | 51.33 | 8.15 Bn |
| 198 | IMVT | Immunovant, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.10 Bn | -14.99 | — | 8.10 Bn |
| 199 | SYRE | Spyre Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.84 Bn | -42.14 | — | 7.84 Bn |
| 200 | GIFLF | Grifols SA | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.54 Bn | 29.70 | 0.46 | 9.09 Bn |
| 201 | RYTM | Rhythm Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.07 Bn | -33.52 | 29.47 | 6.74 Bn |
| 202 | BLRX | BioLineRx Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.97 Bn | -734.96 | 5,007.81 | 6.97 Bn |
| 203 | SRRK | Scholar Rock Holding Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.73 Bn | -17.90 | — | 6.73 Bn |
| 204 | CGON | CG Oncology, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.59 Bn | -29.38 | 1,058.74 | 6.59 Bn |
| 205 | MIRM | Mirum Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.53 Bn | -7.43 | 10.57 | 6.10 Bn |
| 206 | BLCO | Bausch & Lomb Corp | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 6.45 Bn | -39.59 | 1.21 | 6.14 Bn |
| 207 | COGT | Cogent Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.96 Bn | -16.08 | — | 5.96 Bn |
| 208 | DBVT | DBV Technologies S.A. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.84 Bn | -33.18 | 1,163.52 | 5.66 Bn |
| 209 | ORKA | Oruka Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.82 Bn | — | — | 4.09 Bn |
| 210 | XENE | Xenon Pharmaceuticals Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.78 Bn | -16.41 | — | 5.78 Bn |
| 211 | PTCT | Ptc Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.77 Bn | 15.04 | 5.72 | 3.55 Bn |
| 212 | LGND | Ligand Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.69 Bn | 29.05 | 19.58 | 4.33 Bn |
| 213 | AMRX | Amneal Pharmaceuticals, Inc. | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 5.57 Bn | 25.85 | 1.79 | 5.53 Bn |
| 214 | ERAS | Erasca, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.06 Bn | -17.55 | — | 5.06 Bn |
| 215 | FMCQF | Fresenius Medical Care AG | secondary | H-14 | Healthcare Providers | HG-04 | 4.79 Bn | 4.57 | 0.17 | 4.09 Bn |
| 216 | CELC | Celcuity Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.68 Bn | -23.96 | — | 4.68 Bn |
| 217 | DNTH | Dianthus Therapeutics, Inc. /DE/ | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.63 Bn | — | — | 4.23 Bn |
| 218 | RLAY | Relay Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.16 Bn | -13.51 | 402.01 | 4.16 Bn |
| 219 | VKTX | Viking Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.07 Bn | -7.58 | — | 4.07 Bn |
| 220 | DYN | Dyne Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.02 Bn | -7.78 | — | 4.02 Bn |
| 221 | IOVA | Iovance Biotherapeutics, Inc. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 3.98 Bn | -18.93 | 12.25 | 3.68 Bn |
| 222 | IDYA | IDEAYA Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.84 Bn | -16.67 | 16.41 | 3.01 Bn |
| 223 | AMLX | Amylyx Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.80 Bn | -31.20 | — | 3.80 Bn |
| 224 | TNGX | Tango Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.79 Bn | -32.98 | 70.47 | 2.78 Bn |
| 225 | RCUS | Arcus Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.77 Bn | -8.13 | 32.18 | 3.06 Bn |
| 226 | TLPPF | Telix Pharmaceuticals Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.72 Bn | -521.64 | 4.64 | 3.43 Bn |
| 227 | DNLI | Denali Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.56 Bn | -8.16 | 987.61 | 3.56 Bn |
| 228 | ABCL | AbCellera Biologics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.50 Bn | -21.21 | 52.94 | 3.50 Bn |
| 229 | CLDX | Celldex Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.11 Bn | -10.05 | 19,714.47 | 3.11 Bn |
| 230 | IRON | Disc Medicine, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.04 Bn | -15.22 | — | 3.04 Bn |
| 231 | IMNM | Immunome Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.03 Bn | -11.21 | 593.06 | 2.51 Bn |
| 232 | ARQT | Arcutis Biotherapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.00 Bn | 109.49 | 6.47 | 2.76 Bn |
| 233 | MBX | MBX Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.96 Bn | -28.23 | — | 2.96 Bn |
| 234 | ZLAB | Zai Lab Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.94 Bn | -15.57 | 6.55 | 2.24 Bn |
| 235 | SLS | SELLAS Life Sciences Group, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.80 Bn | -80.78 | — | 2.80 Bn |
| 236 | ATAI | AtaiBeckley Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.73 Bn | -22.89 | 553.22 | 2.73 Bn |
| 237 | NRIX | Nurix Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.71 Bn | -8.51 | 73.73 | 2.27 Bn |
| 238 | CURLF | Curaleaf Holdings, Inc. | secondary | S-09 | Tobacco and Cannabis | SG-04 | 2.61 Bn | -21.89 | 2.00 | 2.52 Bn |
| 239 | VRDN | Viridian Therapeutics, Inc.\DE | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.60 Bn | -6.02 | 36.49 | 2.60 Bn |
| 240 | AXGN | Axogen, Inc. | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 2.59 Bn | -174.08 | 10.31 | 2.48 Bn |
| 241 | VERA | Vera Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.59 Bn | -6.44 | — | 2.59 Bn |
| 242 | BCRX | Biocryst Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.54 Bn | -6.59 | 4.75 | 2.19 Bn |
| 243 | BHC | Bausch Health Companies Inc. | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 2.45 Bn | -2.25 | 0.23 | 1.58 Bn |
| 244 | NKTR | Nektar Therapeutics | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.45 Bn | -20.64 | 44.92 | 1.77 Bn |
| 245 | XTLB | Xtl Biopharmaceuticals Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.38 Bn | -2,975.41 | — | 2.38 Bn |
| 246 | SRPT | Sarepta Therapeutics, Inc. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 2.38 Bn | -17.30 | 1.20 | 1.58 Bn |
| 247 | BHVN | Biohaven Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.37 Bn | -4.03 | — | 2.10 Bn |
| 248 | OCUL | Ocular Therapeutix, Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.34 Bn | -7.91 | 44.88 | 2.34 Bn |
| 249 | PHVS | Pharvaris N.V. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.30 Bn | -10.51 | — | 1.93 Bn |
| 250 | KOD | Kodiak Sciences Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.22 Bn | -9.16 | — | 2.22 Bn |
| 251 | RAPP | Rapport Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.19 Bn | -15.84 | 109.75 | 2.19 Bn |
| 252 | ADMA | Adma Biologics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.17 Bn | 13.20 | 4.23 | 2.03 Bn |
| 253 | GMAB | Genmab A/S | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.16 Bn | 0.17 | 0.34 | 0.66 Bn |
| 254 | URGN | UroGen Pharma Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.16 Bn | -35.67 | 11.42 | 2.05 Bn |
| 255 | ZYME | Zymeworks Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.08 Bn | -14.21 | 56.15 | 1.81 Bn |
| 256 | ZBIO | Zenas BioPharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.08 Bn | -4.99 | 2,082.32 | 2.08 Bn |
| 257 | XNCR | Xencor Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.98 Bn | -12.36 | 18.84 | 1.60 Bn |
| 258 | AGIO | Agios Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.97 Bn | -4.78 | 20.06 | 1.97 Bn |
| 259 | RXRX | Recursion Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.94 Bn | -3.72 | 35.35 | 1.39 Bn |
| 260 | VIR | Vir Biotechnology, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.93 Bn | -7.59 | 6.35 | 1.93 Bn |
| 261 | STOK | Stoke Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.86 Bn | -9.47 | 67.43 | 1.57 Bn |
| 262 | IMCR | Immunocore Holdings plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.86 Bn | -101.76 | 4.32 | 0.98 Bn |
| 263 | DMRA | Damora Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.86 Bn | -6.99 | — | 1.32 Bn |
| 264 | SNDX | Syndax Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.83 Bn | -10.09 | 7.27 | 1.29 Bn |
| 265 | CMPS | COMPASS Pathways plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.80 Bn | -4.55 | — | 1.80 Bn |
| 266 | INBX | Inhibrx Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.78 Bn | -14.23 | 1,370.98 | 1.78 Bn |
| 267 | GHRS | GH Research PLC | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.75 Bn | -27.67 | — | 1.39 Bn |
| 268 | SCNI | Scinai Immunotherapeutics Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.74 Bn | -207.39 | 1,008.79 | 1.73 Bn |
| 269 | GLPGF | Lakefront Biotherapeutics NV | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.73 Bn | 0.00 | 1.50 | 1.73 Bn |
| 270 | TYRA | Tyra Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.71 Bn | -12.73 | — | 1.71 Bn |
| 271 | ANIP | Ani Pharmaceuticals Inc | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 1.70 Bn | 13.96 | 1.74 | 1.34 Bn |
| 272 | NVAX | Novavax Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.68 Bn | -6.79 | 4.07 | 0.97 Bn |
| 273 | SEPN | Septerna, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.68 Bn | -118.55 | 16.97 | 1.68 Bn |
| 274 | AAPG | Ascentage Pharma Group International | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.66 Bn | -9.11 | 20.12 | 1.38 Bn |
| 275 | ANAB | Anaptysbio, Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.65 Bn | -68.24 | 8.28 | 1.36 Bn |
| 276 | FBRX | Forte Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.58 Bn | -20.71 | — | 1.23 Bn |
| 277 | BCAX | Bicara Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.53 Bn | -8.49 | — | 1.53 Bn |
| 278 | ABSI | Absci Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.51 Bn | -11.47 | 969.66 | 1.31 Bn |
| 279 | RARE | Ultragenyx Pharmaceutical Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.51 Bn | -3.37 | 2.10 | 1.22 Bn |
| 280 | AVBP | ArriVent BioPharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.50 Bn | -9.00 | — | 1.50 Bn |
| 281 | MAZE | Maze Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.45 Bn | -14.58 | 72.74 | 1.45 Bn |
| 282 | CGEM | Cullinan Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.42 Bn | -6.70 | — | 1.42 Bn |
| 283 | ALMS | Alumis Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.38 Bn | -5.85 | 165.97 | 0.88 Bn |
| 284 | OMER | Omeros Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.37 Bn | 80.09 | 35.55 | 1.37 Bn |
| 285 | VOR | Vor Biopharma Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.36 Bn | -1.48 | — | 1.36 Bn |
| 286 | ORIC | Oric Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.33 Bn | -8.83 | — | 1.33 Bn |
| 287 | SDGR | Schrodinger, Inc. | secondary | T-27 | Vertical Software | TG-05 | 1.32 Bn | -27.62 | 5.09 | 0.90 Bn |
| 288 | IMTX | Immatics N.V. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.28 Bn | -4.85 | 26.37 | 0.82 Bn |
| 289 | MLTX | MoonLake Immunotherapeutics | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.28 Bn | -4.18 | — | 0.74 Bn |
| 290 | JBIO | Jade Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.26 Bn | -7.93 | — | 1.26 Bn |
| 291 | REPL | Replimune Group, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.26 Bn | -4.90 | — | 1.26 Bn |
| 292 | MNKD | Mannkind Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.26 Bn | -28.78 | 3.20 | 1.15 Bn |
| 293 | ANRO | Alto Neuroscience, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.25 Bn | -18.17 | — | 1.25 Bn |
| 294 | JANX | Janux Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.24 Bn | -12.42 | 51.51 | 1.24 Bn |
| 295 | CRVS | Corvus Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.21 Bn | -27.82 | — | 1.00 Bn |
| 296 | CLYM | Climb Bio, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.18 Bn | -20.55 | — | 1.18 Bn |
| 297 | GLUE | Monte Rosa Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.18 Bn | -9.12 | 41.06 | 0.55 Bn |
| 298 | SVRA | Savara Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.10 Bn | -9.77 | — | 1.10 Bn |
| 299 | OKYO | OKYO Pharma Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.06 Bn | -118.02 | — | 1.06 Bn |
| 300 | ABUS | Arbutus Biopharma Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.02 Bn | 6.67 | 5.60 | 0.93 Bn |